What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2021-06-10 compared with 2021-03-11 · 22 added, 13 removed, 6 unchanged (85% of the section changed)

Other Information .

10.1 Amendment to License Agreement between Certainty Therapeutics, Inc.

and The Wistar Institute of Anatomy and Biology.

(Certain information has been redacted in the marked portions of the exhibit.)

10.2 Joint Development and Option Agreement, dated January 26, 2021, between the Company and The Cleveland Clinic Foundation.

(Certain information has been redacted in the marked portions of the exhibit.)

31.1 Certification of Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated March 11, 2021.

31.2 Certification of Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated March 11, 2021.

32.1 Statement of Chief Executive Officer, pursuant to Section 1350 of Title 18 of the United States Code, dated March 11, 2021.

32.2 Statement of Chief Financial Officer, pursuant to Section 1350 of Title 18 of the United States Code, dated March 11, 2021.

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf

by the undersigned, thereunto duly authorized.

ANIXA BIOSCIENCES, INC.

10.1 Assignment

Agreement dated May 1, 2021, between the Company, OntoChem GmbH and MolGenie GmbH.

10.2 Amendment

2 to the Collaboration Agreement between the Company and MolGenie GmbH.

(C ertain information has been redacted

in the marked portions of the exhibit.)

31.1 Certification

of Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated

June 10, 2021.

31.2 Certification

of Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated

June 10, 2021.

32.1 Statement

of Chief Executive Officer, pursuant to Section 1350 of Title 18 of the United States Code,

dated June 10,2021.

32.2 Statement

of Chief Financial Officer, pursuant to Section 1350 of Title 18 of the United States Code,

dated June 10, 2021.

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by

the undersigned, thereunto duly authorized.

BIOSCIENCES, INC.

President and

3 unchanged sentences

Financial Officer

Financial and Accounting

Financial and

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information